| Enhancer activation by pharmacologic displacement of LSD1 from GFI1 induces differentiation in acute myeloid leukemia A Maiques-Diaz, GJ Spencer, JT Lynch, F Ciceri, EL Williams, ... Cell reports 22 (13), 3641-3659, 2018 | 174 | 2018 |
| Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress to date DP Mould, AE McGonagle, DH Wiseman, EL Williams, AM Jordan Medicinal research reviews 35 (3), 586-618, 2015 | 167 | 2015 |
| Development and evaluation of selective, reversible LSD1 inhibitors derived from fragments JR Hitchin, J Blagg, R Burke, S Burns, MJ Cockerill, EE Fairweather, ... MedChemComm 4 (11), 1513-1522, 2013 | 79 | 2013 |
| Toxoflavins and deazaflavins as the first reported selective small molecule inhibitors of tyrosyl-DNA phosphodiesterase II A Raoof, P Depledge, NM Hamilton, NS Hamilton, JR Hitchin, GV Hopkins, ... Journal of medicinal chemistry 56 (16), 6352-6370, 2013 | 74 | 2013 |
| Development of (4-cyanophenyl) glycine derivatives as reversible inhibitors of lysine specific demethylase 1 DP Mould, C Alli, U Bremberg, S Cartic, AM Jordan, M Geitmann, ... Journal of Medicinal Chemistry 60 (19), 7984-7999, 2017 | 43 | 2017 |
| The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity R Newton, KA Bowler, EM Burns, PJ Chapman, EE Fairweather, ... European Journal of Medicinal Chemistry 112, 20-32, 2016 | 33 | 2016 |
| Cell-active small molecule inhibitors of the DNA-damage repair enzyme poly (ADP-ribose) glycohydrolase (PARG): discovery and optimization of orally bioavailable … B Waszkowycz, KM Smith, AE McGonagle, AM Jordan, B Acton, ... Journal of medicinal chemistry 61 (23), 10767-10792, 2018 | 27 | 2018 |
| Development of 5-hydroxypyrazole derivatives as reversible inhibitors of lysine specific demethylase 1 DP Mould, U Bremberg, AM Jordan, M Geitmann, A Maiques-Diaz, ... Bioorganic & Medicinal Chemistry Letters 27 (14), 3190-3195, 2017 | 20 | 2017 |
| Development and evaluation of 4-(pyrrolidin-3-yl) benzonitrile derivatives as inhibitors of lysine specific demethylase 1 DP Mould, U Bremberg, AM Jordan, M Geitmann, AE McGonagle, ... Bioorganic & Medicinal Chemistry Letters 27 (20), 4755-4759, 2017 | 12 | 2017 |
| Abstract C39: First-in-class inhibitors of the putatively undruggable DNA repair target Poly (ADP-ribose) glycohydrolase (PARG) B Waszkowycz, D James, B Acton, E Fairweather, S Fritzl, N Hamilton, ... Molecular Cancer Therapeutics 14 (12_Supplement_2), C39-C39, 2015 | 1 | 2015 |
| Abstract B98: Development and evaluation of selective, reversible LSD1 inhibitors from fragment startpoints. A Stowell, N Hamilton, J Hitchin, J Blagg, R Burke, S Burns, MJ Cockerill, ... Molecular Cancer Therapeutics 12 (11_Supplement), B98-B98, 2013 | 1 | 2013 |
| Design and Development of Reversible Inhibitors of Lysine Specific Demethylase 1 D Mould The University of Manchester, Manchester, UK, 2017 | | 2017 |
| Discovery and optimization of the first sub-micromolar, cell permeable, small molecule inhibitors of poly (ADP ribose) glycohydrolase (PARG) A McGonagle, B Acton, J Ahmet, P Chapman, E Fairweather, L Griffiths, ... ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 252, 2016 | | 2016 |
| Optimisation of quinazolinedione sulphonamides as novel inhibitors of poly (ADP Ribose) glycohydrolase (PARG) K Smith, B Acton, D James, C Jones, S Jones, A Jordan, N Hamilton, ... Cancer Research 76 (14_Supplement), 3714-3714, 2016 | | 2016 |
| The identification and structure-guided optimisation of potent and selective inhibitors of oncogenes in medullary thyroid carcinoma and lung adenocarcinoma R Butlin, R Newton, M Watson, G Hopkins, B Acton, K Bowler, S Fritzl, ... Cancer Research 75, 2015 | | 2015 |
| The discovery and optimisation of small-molecule inhibitors of human 5’-tyrosyl DNA phosphodiesterase (Tdp2). AM Jordan, P Depledge, N Hamilton, J Hitchin, G Hopkins, L Maguire, ... Cancer Research 73 (8_Supplement), 3324-3324, 2013 | | 2013 |
| The discovery and optimisation of small-molecule inhibitors of human 5’-tyrosyl DNA phosphodiesterase (Tdp2) I Waddell, AM Jordan, P Depledge, N Hamilton, JR Hitchin, G Hopkins, ... AACR 2012, 2013 | | 2013 |
| Development and evaluation of selective, reversible, LSD1 inhibitorsfrom fragment start points I Waddell, A Stowell, N Hamilton, J Blagg, R Burke, S Burns, M Cockerill, ... EORTC, 2013 | | 2013 |
